



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

August 19, 2022

James N. Topper
Chief Executive Officer and Chairman
Frazier Lifesciences Acquisition Corp
Two Union Square
601 Union St., Suite 3200
Seattle, WA 98101

Re: Frazier Lifesciences Acquisition Corp
Form 10-K for the Fiscal Year Ending December 31, 2021
Filed March 25, 2022
File No. 001-39765

Dear James N. Topper:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Real Estate & Construction